Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

NCT02715193 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus
Diabetes

Interventions

BIOLOGICAL: REMD-477
BIOLOGICAL: Placebo Comparator

Sponsor

REMD Biotherapeutics, Inc.